

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

SNU-C5

RRID:CVCL_5112

Type: Cell Line

Proper Citation

RRID:CVCL_5112

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5112

Proper Citation: RRID:CVCL_5112

Description: Cell line SNU-C5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Cecum adenocarcinoma

Defining Citation: [PMID:3479249](#), [PMID:8556707](#), [PMID:8806092](#), [PMID:8806095](#), [PMID:19956504](#), [PMID:22460905](#), [PMID:25926053](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28854368](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Established from a nude mouse xenograft., Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-C5

Synonyms: SNUC5, NCI-SNU-C5, SNU-C5/WT

Cross References: CLO:CLO_0037285, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:1023, BioSample:SAMN10987753, cancercellines:CVCL_5112, Cell_Model_Passport:SIDM00498, CLS:305639, ColonAtlas:SNUC5, Cosmic-CLP:1674021, DepMap:ACH-000970, EGA:EGAS00001000978, GDSC:1674021, GEO:GSM887646, GEO:GSM888738,

GEO:GSM1448131, GEO:GSM1670478, IARC_TP53:5453, KCLB:0000C5, LiGeA:CCLE_017, PharmacDB:SNUC5_1493_2019, PRIDE:PXD005235, PRIDE:PXD018763, PRIDE:PXD030304, Progenetix:CVCL_5112, PubChem_Cell_line:CVCL_5112, Wikidata:Q54955295

ID: CVCL_5112

Record Creation Time: 20220427T221553+0000

Record Last Update: 20260913T010058+0000

Ratings and Alerts

No rating or validation information has been found for SNU-C5.

No alerts have been found for SNU-C5.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tak E, et al. (2025) Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer. Cancer immunology, immunotherapy : CII, 74(5), 154.

Zhang C, et al. (2025) Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e12074.